CLINICAL_TRIALS
trial_result
· 2022-06-23
Clinical Trial Update: Decitabine and Talazoparib in Untreated AML and R/R AML [Phase 1, Phase 2]
Summary
Phase 1/2 trial evaluating decitabine with talazoparib in untreated and relapsed/refractory acute myeloid leukemia has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Maryland, Baltimore | Conditions: Acute Myeloid Leukemia | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-06-23